

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/634,641	
			Filing Date	August 4, 2003	
			First Named Inventor	TAKAHATA, KYOYA	
			Art Unit	1814	
Examiner Name	Not Yet Assigned				
Attorney Docket Number	ORIN-004				
Sheet	1	of	3		

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
cm		US- 6,022,718		02/08/2000	Iwai et al.	
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² -Number ⁴ -Kind Code ³ (if known)					
cm		WO 00/16756		03/30/2000	Innovet Italia S.R.L.		

Examiner Signature	cm	Date Considered	7.6.05
-----------------------	----	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/634,641
		Filing Date	August 4, 2003
		First Named Inventor	TAKAHATA, KYOYA
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet 2 of 3	Attorney Docket Number	ORIN-004	
OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cm		MELCK, et al., "Suppression of nerve Growth Factor Trk. receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation," Endocrinology, vol. 141, no. 1, pgs. 118-126 (2000) (Document No. XP-002272763)	
		MELCK, et al., "Unsaturated long-chain N-Acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to SB1 cannabinoid receptors," Biochemical and Biophysical Research Communications, Academic Press Inc., vol. 9, no. 13, pgs. 275-284 (Document No. XP-000892119)	
		JACOBSSON, et al., "Inhibition of rat c6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors," Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and Experimental Therapeutics, vol. 299, no. 3, pgs 951-959 (2001) (Document No. XP-001120403)	
		DE PETROVELLIS, et al. "Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders," Chemistry and Physics of Lipids, vol. 108, pgs. 191-209 (2000) (Document No. XP-002941399)	
		DI MARZO, et al., "Highly selective CB ₁ cannabinoid receptor ligands and novel CB ₁ / VR ₁ vanilloid receptor "hybrid" ligands," Biochemical and Biophysical Research Communications, vol. 281, no. 2, pgs. 444-451 (2001) (Document No. XP-002272764)	
		TAKAHATA, et al., "Inducing effect of cancer cell apoptosis by docosahexaenoic acid (DHA) derivatives (Dohevanil) of a hot ingredient of red pepper, capsaicin," New Food Industry, 44(10), 6-10, (2002) (Document No. XP-009026691) and English Translation Provided	+
✓		KEISUKE, et al., "Homovanillic acid derivative, capsaicin, induces apoptosis of myeloid leukemic cell via a p53-dependent pathway in vitro and in vivo," Database Accession no. PREV 200300368073, Blood, vol. 100, no. 11 (2002-11-16) pg. Abstract no. 4589, 44 th Annual Meeting of the American Society of Hematology, Philadelphia PA (Dec. 6-10, 2002) (Document No. XP-0022722766)	
Examiner Signature	cm		Date Considered 7/6/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/634,641
		Filing Date	August 4, 2003
		First Named Inventor	TAKAHATA, KYOYA
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet	3	of	3
		Attorney Docket Number	ORIN-004

cm	PATEL, et al., "Capsaicin regulates vascular endothelial cell growth factor expression by modulation of hypoxia inducing factor-1 α in human malignant melanoma cells," J. Cancer Res Clin Oncol, vol. 128, pgs 461-468 (2002) (Document No. XP-002272765)
	DI MARZO, et al., "Interactions between synthetic vanilloids and the endogenous cannabinoid system," FEBS Letters, Elsevier Science Publishers, Amsterdam, NL., vol. 436, no. 3, pgs. 449-454 (1998) (Document No. XP-004258472)
	SHERWIN, et al., "Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces," Proc. Natl. Acad. Sci. USA, vol. 76, no. 3, pgs. 1288-1292 (1997) (Document No. XP-009026810)
✓	DE CABO, et al., "Inhibition of growth and metastasis of B-16 mouse melanoma cells inhibited by capsaicin," Molecular Biology of the cell, vol. 7, no. Suppl, pg 172A (1996) (Document No. XP-009026810)

Examiner Signature	cm	Date Considered	7/6/05
-----------------------	----	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.